{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T08:17:43Z","timestamp":1788250663039,"version":"build-2803163510"},"reference-count":22,"publisher":"Faculty of Pharmacy and Pharmaceutical Sciences, University of Karachi","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,1]]},"abstract":"<jats:p>Background: Edaravone can reduce damage to brain cells in a variety of ways. Rho\/ROCK signaling is involved in Alzheimer's disease. Objectives: This study uses AD cell models to explore edaravone\u2019s effect on AD nerve synapse damage. Methods: The ROCK2 promoter luciferase reporter gene was constructed, A?25-35 was used as a processing factor and transfected into PC12 cells to construct an AD cell model which was then treated with edaravone, followed by analysis of 95 antibody (PSD95), synapse-related mRNA synapsin 1 (SYN1) level to observe its effect on Rho\/ROCK signaling. Results: Edaravone can effectively inhibit the transcriptional activity of ROCK2 promoter in AD cell model, upregulate SYN1 and GAP43 protein and downregulate ROCK2. After ROCK2 overexpression, edaravone can affect SYN1 expression in AD cell model, while SYN1 expression did not change significantly after ROCK2 was silenced. Conclusion: Edaravone has a protective effect on AD nerve synapse damage and plays a role in repairing nerve synapse damage through ROCK2 signaling pathway.<\/jats:p>","DOI":"10.36721\/pjps.2026.39.6.154.1","type":"journal-article","created":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T12:17:29Z","timestamp":1775305049000},"source":"Crossref","is-referenced-by-count":0,"title":["Effect Of Edaravone On Synaptic Damage In Alzheimer's Disease Via Rho\/ROCK Signaling"],"prefix":"10.36721","author":[{"given":"Yuejun","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"22735","published-online":{"date-parts":[[2026,3,28]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"Abe K, Shang JW, Shi XW, Yamas HT, Hishikawa N, Takemoto M, Morihara R, Nakano Y, Ohta Y, Deguchi K, Ikeda M, Ikeda Y, Okamoto K, Shoji M, Takatama M, Kojo M, Kuroda T, Ono K, Kimura N, Matsubara E, Osakada Y, Wakutani Y, Takao Y, Higashi Y, Asada K, Senga T, Lee LJ and Tanaka K (2020). A new serum biomarker set to detect mild cognitive impairment and Alzheimer's disease by peptidome technology. J. Alzheimers Dis., 73(1): 217-227.","DOI":"10.3233\/JAD-191016"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Aksnes M, Aass HCD, Tiiman A, Terenius L, Bogdanovi N, Vukojevi V and Knapskog AB (2022). Serum amyloidogenic nanoplaques and cytokines in alzheimer's disease: Pilot study in a small naturalistic memory clinic cohort. J. Alzheimers Dis., 86(3): 1459-1470.","DOI":"10.3233\/JAD-215504"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Arnold M, Nho K, Kueider-Paisley A, Massaro T, Huynh K, Brauner B, MahmoudianDehkordi S, Louie G, Moseley MA, Thompson JW, St John-Williams L, Tenenbaum JD, Blach C, Chang R, Brinton RD, Baillie R, Han XL, Trojanowski JQ, Shaw LM, Martins R, Weiner MW, Trushina E, Toledo JB, Meikle PJ, Bennett DA, Krumsiek J, Doraiswamy PM, Saykin AJ, Kaddurah-Daouk R and Kastenm\u00fcller G (2020). Sex and  \u03b54 genotype modify the Alzheimer's disease serum metabolome. Nat Commun., 11(1): 1148.","DOI":"10.1038\/s41467-020-14959-w"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Bharani KL, Ledreux A, Gilmore A, Carroll SL and Granholm AC (2020). Serum pro-BDNF levels correlate with phospho-tau staining in Alzheimer's disease. Neurobiol. Aging., 87: 49-59.","DOI":"10.1016\/j.neurobiolaging.2019.11.010"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Calvo N and Einstein G (2023). Steroid hormones: Risk and resilience in women's Alzheimer disease. Front. Aging Neurosci., 15: 1159435.","DOI":"10.3389\/fnagi.2023.1159435"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Gao H, Liu M, Zhao Z, Yang C, Zhu L, Cai Y, Yang Y and Hu Z (2020). Diagnosis of mild cognitive impairment and Alzheimer's disease by the plasma and serum amyloid-beta 42 assay through highly sensitive peptoid nanosheet sensor. ACS Appl Mater Interfaces, 12(8): 9693-9700.","DOI":"10.1021\/acsami.0c00370"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Ghasemi M, Turnbull T, Sebastian S and Kempson I (2021). The MTT assay: Utility, limitations, pitfalls and interpretation in bulk and single-cell analysis. Int J Mol Sci., 22(23): 12827.","DOI":"10.3390\/ijms222312827"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Hassan R, Rabea AA, Ragae A and Sabry D (2020). The prospective role of mesenchymal stem cells exosomes on circumvallate taste buds in induced Alzheimer's disease of ovariectomized albino rats: (Light and transmission electron microscopic study). Arch Oral Biol, 110: 104596.","DOI":"10.1016\/j.archoralbio.2019.104596"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Lakshmanan I and Batra SK (2013). Protocol for apoptosis assay by flow cytometry using annexin v staining method. Bio Protoc., 3(6): e374.","DOI":"10.21769\/BioProtoc.374"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Liu M, Li F, Yan H, Wang K, Ma Y, Alzheimer's Disease Neuroimaging I, Shen L and Xu M (2020a). A multi-model deep convolutional neural network for automatic hippocampus segmentation and classification in Alzheimer's disease. Neuroimage, 208: 116459.","DOI":"10.1016\/j.neuroimage.2019.116459"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Liu Y, Zhong X, Shen JJ, Jiao LC, Tong JH, Zhao WX, Du K, Gong SQ, Liu MY and Wei MJ (2020b). Elevated serum TC and LDL-C levels in Alzheimer's disease and mild cognitive impairment: A meta-analysis study. Brain Res., 1727: 146554.","DOI":"10.1016\/j.brainres.2019.146554"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Lu G, Liu W, Huang X and Zhao Y (2020). Complement factor H levels are decreased and correlated with serum C-reactive protein in late-onset Alzheimer's disease. Arq Neuropsiquiatr, 78(2): 76-80.","DOI":"10.1590\/0004-282x20190151"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Lu XY, Li MQ, Li YT, Yao JY, Zhang LX, Zeng ZH, Chen ZR, Li CQ, Zhou XF and Li F (2024). Oral edaravone ameliorates behavioral deficits and pathologies in a valproic acid-induced rat model of autism spectrum disorder. Neuropharmacology, 258: 110089.","DOI":"10.1016\/j.neuropharm.2024.110089"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Mehri N, Haddadi R, Ganji M, Shahidi S, Soleimani Asl S, Taheri Azandariani M and Ranjbar A (2020). Effects of vitamin D in an animal model of Alzheimer's disease: Behavioral assessment with biochemical investigation of Hippocampus and serum. Metab Brain Dis., 35(2): 263-274.","DOI":"10.1007\/s11011-019-00529-7"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Quiroz YT, Zetterberg H, Reiman EM, Chen YH, Su Y, Fox-Fuller JT, Garcia G, Villegas A, Sepulveda-Falla D, Villada M, Arboleda-Velasquez JF, Guzman-Velez E, Vila-Castelar C, Gordon BA, Schultz SA, Protas HD, Ghisays V, Giraldo M, Tirado V, Baena A, Munoz C, Rios-Romenets S, Tariot PN, Blennow K and Lopera F (2020). Plasma neurofilament light chain in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: A cross-sectional and longitudinal cohort study. Lancet Neurol., 19(6): 513-521.","DOI":"10.1016\/S1474-4422(20)30137-X"},{"key":"ref15","unstructured":"Rao X, Huang X, Zhou Z and Lin X (2013). An improvement of the 2^(-delta delta CT) method for quantitative real-time polymerase chain reaction data analysis. Biostat Bioinforma Biomath, 3(3): 71-85."},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Shamsi A, Mohammad T, Anwar S, Alajmi MF, Hussain A, Hassan MI, Ahmad F and Islam A (2020). Probing the interaction of rivastigmine tartrate, an important Alzheimer's drug, with serum albumin: Attempting treatment of Alzheimer's disease. Int J Biol Macromol, 148: 533-542.","DOI":"10.1016\/j.ijbiomac.2020.01.134"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Sheu JJ, Yang LY, Sanotra MR, Wang ST, Lu HT, Kam RSY, Hsu IU, Kao SH, Lee CK, Shieh JC and Lin YF (2020). Reduction of AHI1 in the serum of Taiwanese with probable Alzheimer's disease. Clin Biochem, 76: 24-30.","DOI":"10.1016\/j.clinbiochem.2019.11.011"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Vignoli A, Bellomo G, Paoletti FP, Luchinat C, Tenori L and Parnetti L (2025). Studying Alzheimer's disease through an integrative serum metabolomic and lipoproteomic approach. J. Transl Med., 23(1): 119.","DOI":"10.1186\/s12967-025-06148-4"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Zegarra-Valdivia JA, Pignatelli J, Nu\u00f1ez A and Aleman IT (2023). The Role of insulin-like growth factor I in mechanisms of resilience and vulnerability to sporadic Alzheimer's disease. Int. J. Mol. Sci., 24(22): 16440.","DOI":"10.3390\/ijms242216440"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Zhang Z, Yi P, Yang J, Huang J, Xu P, Hu M, Zhang C, Wang B and Peng W (2020). Integrated network pharmacology analysis and serum metabolomics to reveal the cognitive improvement effect of Bushen Tiansui formula on Alzheimer's disease. J Ethnopharmacol., 249: 112371.","DOI":"10.1016\/j.jep.2019.112371"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Zhao LQ, Parikh A, Xiong YX, Ye QY, Ying-Guo, Zhou XF and Luo HY (2022). Neuroprotection of oral edaravone on middle cerebral artery occlusion in rats. Neurotox. Res., 40(4): 995-1006.","DOI":"10.1007\/s12640-022-00520-8"}],"container-title":["Pakistan Journal of Pharmaceutical Sciences"],"original-title":[],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T07:56:13Z","timestamp":1788249373000},"score":1,"resource":{"primary":{"URL":"https:\/\/pjps.pk\/single-article?id=7757"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,28]]},"references-count":22,"URL":"https:\/\/doi.org\/10.36721\/pjps.2026.39.6.154.1","relation":{},"ISSN":["1011-601X","3105-9686"],"issn-type":[{"value":"1011-601X","type":"print"},{"value":"3105-9686","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,28]]}}}